MedTrace Logo

In Vivo Assessment of Silver Biomaterial Nano-Toxicity

NCT01243320 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-08-25

Study results available
· View outcomes & findings →

Summary

Nanotechnology is the controlled generation and manipulation of matter in dimensions less than 100 nm. Silver has been used for its bactericidal properties. The investigators propose to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human volunteers to determine the toxicity and to quantify cytochrome P450 enzyme effects of this solution.

Conditions

  • Healthy

Interventions

DRUG

10ppm Oral Silver Particle

Silver nanoparticles at 10ppm

DRUG

32ppm Oral Silver Particle

Silver nanoparticles at 32ppm

Sponsors & Collaborators

Principal Investigators

  • Mark A Munger, Pharm.D> · University of Utah

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243320 on ClinicalTrials.gov